Zilovertamab
Based on 2 publication(s) in Google Scholar
Zilovertamab (UC-961) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.21%
- CAS 番号: 2485779-13-1
- 分子量:145.12 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Zilovertamab
More
生物活性
Human IgG1 kappa
Human
|
Wnt5A |
Zilovertamab (25 and 50 μg/mL; 72 h) inhibits high-grade serous ovarian cancer (HGSOC) cell proliferation[1].
Zilovertamab (50 μg/mL; 72 h) down-regulates ROR1 expression levels in CaOV3 at the transcriptional level[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CaOV3, CaOV3CisR, PEO1, and PEO4 cells
-
Concentration:25 and 50 µg/mL
-
Incubation Time:72 hours
-
Result:Reduced the proliferation of CaOV3, CaOV3CisR and PEO1.
-
Cell Line:CaOV3, CaOV3CisR, PEO1, and PEO4 cells
-
Concentration:50 µg/mL
-
Incubation Time:72 hours
-
Result:Down-regulated ROR1 expression levels in CaOV3 at the transcriptional level.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Q01973
ROR1
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized Human ROR1-ECD-His can bind Zilovertamab. The EC50 for this effect is 3.078 ng/mL.
化学情報
-
CAS 番号 2485779-13-1
-
性状 Liquid
-
分子量 145.12 kDa
-
Color Colorless to light yellow
-
SMILES
[Zilovertamab]
-
別名
UC-961; Cirmtuzumab
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Mol Ther
Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy. [Abstract]2025 Dec 2:S1525-0016(25)00959-1. PMID: 41338184 -
純度とドキュメンテーション
-
データシート (260 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Zilovertamab 関連分類
HY-P99201 関連分類
Powered by Bioz